Is a complete ALLO research report available?

No complete published report is available for Allogene Therapeutics, Inc. (ALLO) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · USD

$1.74

-0.08 (-4.4%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-26 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ALLO analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	600.6M
Net income (ttm)	-173.8M
EPS (ttm)	-$0.77
Shares out	345.2M
Volume	4,874,170
Beta	0.46
Price target	$9.00	+417.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -173.8M
EPS (ttm): -$0.77
Market cap: 600.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ALLO indicators

Market & fundamental data

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001737287
Company name	Allogene Therapeutics, Inc.
Country	United States
Country code	US
Cusip	019770106
Employees	152
Employees Change	-77%
Employees Change Percent	-33.62
Enterprise value	$414.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2018-10-11
Isin	US0197701065
Last refreshed	2026-07-26
Market cap	$600.6M
Market cap category	Small-Cap
Price	$1.74
Price currency	USD
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2836
Symbol	ALLO
Website	https://allogene.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-28.93%
EV Sales Forward	35,568.95x
FCF yield	-18.24%
P/B ratio	1.53x
PS Forward	51,506.77x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-132M
Net Income	$-173.8M
Net Income Growth Quarters	6%
Net Income Growth Years	3%
Profit Per Employee	$-1.1M
ROA	-25.97
Roa5y	-22.63
ROCE	-51.74
ROE	-52.32
Roe5y	-45.06
ROIC	-28.14

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	4.82%
Cagr3y	-31.44%
Cagr5y	-39.83%
EPS Growth Quarters	11
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$396M
Cash	$266.9M
Current Assets	$273.3M
Current Liabilities	$28.3M
Debt	$81.1M
Debt Equity	$0.29
Equity	$278.9M
Interest Coverage	-155.3
Liabilities	$117.1M
Long Term Assets	$122.7M
Long Term Liabilities	$88.8M
Net Cash	$185.8M
Net Cash By Market Cap	$30.94
Net Cash Growth	-2.77%
Net Debt Equity	$-0.67
Tangible Book Value	$278.9M
Tangible Book Value Per Share	$1.14
WACC	6.12

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.65
Net Working Capital	$-13.5M
Quick ratio	9.47
Working Capital	$245M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.93%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	4.82%
200-day SMA	1.85
3Y total return	-67.78%
50-day SMA	2
50-day SMA vs 200-day SMA	50over200
5Y total return	-92.11%
All Time High	55
All Time High Change	-96.84%
All Time High Date	2020-05-26
All Time Low	0.86
All Time Low Change	101.83%
All Time Low Date	2025-05-14
ATR	0.12
Beta	0.46
Beta1y	2.07
Beta2y	1.7
Ch YTD	27.01
High	1.84
High52	4.46
High52 Date	2026-04-13
High52ch	-60.99%
Low	1.74
Low52	0.98
Low52 Date	2025-08-07
Low52ch	76.79%
Ma50ch	-12.78%
Premarket Change Percent	1.65
Premarket Price	$1.85
Premarket Volume	12,061
Price vs 200-day SMA	-6.1%
RSI	35.78
RSI Monthly	40.86
RSI Weekly	45.37
Sharpe ratio	0.43x
Sortino ratio	0.71
Total Return	-9.93%
Tr YTD	27.01
Tr1m	-15.94%
Tr1w	-2.79%
Tr3m	-25.96%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	5
Analyst Price Target Top	$10.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.15
Earnings Revenue Estimate	2,220x
Operating Income	$-187.8M
Price target	$9
Price Target Change	$417
Price Target Change Top	$503

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	270,625,747%
Float Percent	78.41%
Shares Insiders	4.34%
Shares Institutions	42.53%
Shares Out	345,154,561
Shares Qo Q	6.31%
Shares Yo Y	9.93%
Short Float	23.42%
Short Ratio	6.35
Short Shares	18.36

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-143.3M
Average Volume	9,342,947.65x
Bv Per Share	1.14
CAPEX	$-296,000
Ch1m	-15.94
Ch1w	-2.79
Ch1y	4.82
Ch3m	-25.96
Ch3y	-67.78
Ch5y	-92.11
Ch6m	1.16
Change	-4.4%
Change From Open	-4.92
Close	1.82
Days Gap	0.55
Depreciation Amortization	12,129,000
Dollar Volume	8,481,055.8
Earnings Date	2026-08-12
Earnings Time	amc
EBIT	$-190.2M
EBITDA	$-178.1M
EPS	$-0.77
F Score	1
FCF	$-109.5M
FCF EV Yield	-26.41x
FCF Per Share	$-0.32
Financing CF	37,289,000
Fiscal Year End	December
Founded	2,017
Investing CF	59,795,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-13
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-12
Ma150	2.04
Ma150ch	-14.5%
Ma20	1.97
Ma20ch	-11.63%
Net CF	-12,146,000
Next Earnings Date	2026-08-12
Open	1.83
Optionable	Yes
Position In Range	0
Post Close	1.74
Postmarket Change Percent	0.57
Postmarket Price	$1.75
Ppne	108,842,000
Pre Close	1.82
Price Date	2026-07-24
Ptbv Ratio	2.15
Relative Volume	0.52x
Share Based Comp	33,737,000
Tr6m	1.16%
Us State	California
Volume	4,874,170

Allogene Therapeutics, Inc. (ALLO)

Coverage state: Market snapshot only — no published research

Generate the first ALLO analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ALLO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ALLO indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ALLO

Frequently asked questions